Chen Zhong1,2,
Feng Cheng1,2 
For correspondence:- Feng Cheng Email: shfx86@163.com
Accepted: 27 July 2021 Published: 31 December 2021
Citation: Zhong C, Cheng F. Retracted “Xuebijing injection alleviates liver injury in patients with hepatocellular carcinoma by inhibiting inflammatory response after transarterial chemoembolization”. Trop J Pharm Res 2021; 20(12):2681-2681 doi: 10.4314/tjpr.v20i12.31
© 2021 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
This article previously published in Volume 20 Issue 8 of this journal in August 2021has been retracted in line with the guidelines from the Committee on Publication Ethics (COPE, http://publicationethics.org/resources/guidelines).
Retraction: Zhong C, Cheng F. Xuebijing injection alleviates liver injury in patients with hepatocellular carcinoma by inhibiting inflammatory response after transarterial chemoembolization. Trop J Pharm Res 2021; 20(8):1705-1710 doi: 10.4314/tjpr.v20i8.22.
To the editor:
My institution has noted that half of the data we published violated privacy regulation. Deletion of half of the data will mean that the results will not be reliable. Because of this, coupled with the reputation and fame of your journal, we made a painful decision to retract this article.
Signed: Chen Feng
Archives
News Updates
Fulltext in PDF